サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1555727

無菌注射剤市場：薬剤タイプ別、投与経路別、薬剤クラス別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Sterile Injectable Drugs Market, By Drug Type, By Route of Administration, By Drug Class, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 393 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.88円
無菌注射剤市場：薬剤タイプ別、投与経路別、薬剤クラス別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年08月23日
発行: AnalystView Market Insights
ページ情報: 英文 393 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

無菌注射剤の市場規模は2023年に5,851億2,376万米ドルとなり、2024年から2032年にかけてCAGR7.5％で拡大

無菌注射剤市場 - 市場力学

糖尿病とがん率の上昇が無菌注射剤市場の成長を促進

無菌注射剤市場の成長は、糖尿病やがんなどの慢性疾患の罹患率の上昇によって大きく左右されます。国際糖尿病連合は、世界で約5億3,700万人の成人が糖尿病を患っていると報告しており、効果的な注射治療に対する需要が高まっています。同様に、世界保健機関は、がんが世界の主要死因のひとつであり、2020年だけでも1,000万人が死亡すると推定しています。このような慢性疾患の急増は、正確で効率的な治療選択肢を提供できる先進的で信頼性の高い注射剤へのニーズを高めています。さらに、ドラッグデリバリー技術の進歩により、これらの注射剤の有効性と安全性が向上しており、市場の拡大をさらに後押ししています。

無菌注射剤市場 - 主要洞察

リサーチアナリストの分析によると、世界市場は予測期間（2024年～2032年）にCAGR約7.5%で年間成長すると推定されます。

薬剤タイプ別では、モノクローナル抗体（mAbs）が2023年に最大の市場シェアを示すと予測されています。

投与経路別では、静脈内投与（IV）が2023年の主要タイプでした。

薬剤クラス別では、がん治療薬が2023年の主要タイプでした。

地域別では、北米が2023年の主要売上国でした。

無菌注射剤市場 - セグメンテーション分析：

無菌注射剤の世界市場は、薬剤タイプ、投与経路、薬剤クラス別、エンドユーザー別、地域別に区分されます。

市場は薬剤タイプに基づいて5つのカテゴリーに分けられます：モノクローナル抗体（mAbs）、サイトカイン、インスリン、抗生物質です。モノクローナル抗体（mAbs）は、がんや自己免疫疾患の治療に幅広く応用されているため、無菌注射剤市場で最も高い優先順位を占めています。インスリンは糖尿病管理における重要な役割でこれに続き、ワクチン、サイトカイン、抗生物質はその次です。

市場は投与経路によって3つのカテゴリーに分けられます：静脈内投与、筋肉内投与、皮下投与です。静脈内投与は即効性があり、急性症状にも有効であるため、無菌注射剤市場において最優先されます。次に皮下投与が慢性治療での使いやすさから、そして筋肉内投与が特定の用途のために続いています。

無菌注射剤市場 - 地理的洞察

北米は高度なヘルスケアインフラ、革新的医療技術の高い導入率、医薬品研究開発への多額の投資により市場をリードしています。特に米国は、患者数の多さと強固なヘルスケアシステムに牽引され、無菌注射剤に対する高い需要を示しています。欧州は、ドイツ、フランス、英国などの国々の強力なヘルスケアシステムに支えられ、生物製剤や個別化医療への注目が高まっています。アジア太平洋地域は、慢性疾患の罹患率の上昇、医療インフラの拡大、中国やインドのような国々におけるヘルスケア支出の増加により、急成長を遂げています。ラテンアメリカと中東・アフリカは新興市場であり、ヘルスケア施設の改善と先進治療に対する意識の高まりにより、潜在的な可能性を見せています。

無菌注射剤市場 - 競合情勢：

Pfizer Inc.、Johnson & Johnson、Rocheなどの主要企業が市場をリードしており、医薬品開発と製造における豊富な専門知識を活かして高度な無菌注射剤を提供しています。これらの企業は、新しい製剤の開発や既存製品の改良のための研究に多額の投資を行い、慢性疾患に対する効果的な治療に対する需要の高まりに対応しています。さらに、各社が製品ポートフォリオの拡充と市場でのプレゼンス向上を目指しているため、戦略的な合併や買収も一般的に行われています。新興企業も市場に参入し、斬新なソリューションを提供したり、特殊な製品でニッチなセグメントを狙ったりしています。競合環境は、厳格な規制基準を遵守し、高品質の生産を確保する必要性によってさらに形成され、無菌注射剤技術の絶え間ない革新と改善を推進しています。

目次

第1章 無菌注射剤市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 無菌注射剤の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 無菌注射剤産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 無菌注射剤市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 無菌注射剤市場情勢

  • 無菌注射剤市場シェア分析、2023年
  • 内訳データ：主要メーカー別
    • 既存企業の分析
    • 新興企業の分析

第7章 無菌注射剤市場 - 薬剤タイプ別

  • 概要
    • セグメントシェア分析：薬剤タイプ別
    • モノクローナル抗体（mAbs）
    • サイトカイン
    • インスリン
    • ワクチン
    • 抗生物質

第8章 無菌注射剤市場 - 投与経路別

  • 概要
    • セグメントシェア分析：投与経路別
    • 静脈内（IV）
    • 筋肉内（IM）
    • 皮下（SC）
    • その他

第9章 無菌注射剤市場 - 薬剤クラス別

  • 概要
    • セグメントシェア分析：薬剤クラス別
    • 治療薬
    • 抗凝固剤
    • 腫瘍治療薬
    • 心臓血管薬
    • 抗感染薬

第10章 無菌注射剤市場 - エンドユーザー別

  • 概要
    • セグメントシェア分析：エンドユーザー別
    • 病院
    • 専門クリニック
    • 外来手術センター
    • 研究機関

第11章 無菌注射剤市場 - 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析 - 無菌注射剤業界

  • 競合ダッシュボード
  • 企業プロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca plc
    • Baxter International Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Fresenius Kabi AG
    • GlaxoSmithKline plc
    • Johnson &Johnson
    • Merck &Co., Inc.
    • Mylan NV（now part of Viatris）
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • その他

第13章 アナリストの全方位展望

目次
Product Code: ANV3749

REPORT HIGHLIGHT

Sterile Injectable Drugs Market size was valued at USD 585,123.76 Million in 2023, expanding at a CAGR of 7.5% from 2024 to 2032.

The Sterile Injectable Drugs Market, comprising pharmaceuticals administered via injection under sterile conditions, is expanding due to the increasing prevalence of chronic diseases and the demand for precision therapies. The rise in conditions such as diabetes and cancer, coupled with advancements in drug delivery technologies, is fueling market growth. For example, the International Diabetes Federation estimates that over 537 million adults globally have diabetes, highlighting the significant need for effective injectable treatments. Additionally, advancements in sterile injectable technology are improving the efficiency and safety of drug administration, further driving market potential. However, challenges such as stringent regulatory requirements and high production costs can constrain market expansion. Opportunities exist in the form of growing investments in biologics and the development of advanced drug delivery systems.

Sterile Injectable Drugs Market- Market Dynamics

Rising Diabetes and Cancer Rates Fueling Growth in the Sterile Injectable Drugs Market

The growth of the Sterile Injectable Drugs Market is significantly driven by the rising incidence of chronic diseases such as diabetes and cancer. The International Diabetes Federation reports that approximately 537 million adults worldwide are living with diabetes, increasing the demand for effective injectable treatments. Similarly, the World Health Organization highlights that cancer is one of the leading causes of death globally, with an estimated 10 million deaths in 2020 alone. This surge in chronic disease prevalence is driving the need for advanced and reliable injectable drugs that can offer precise and efficient treatment options. Additionally, advancements in drug delivery technologies are improving the efficacy and safety of these injectables, further supporting market expansion.

Sterile Injectable Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.5% over the forecast period (2024-2032)

Based on Drug Type segmentation, Monoclonal Antibodies (mAbs) were predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Intravenous (IV) was the leading type in 2023

Based on Drug Class segmentation, Oncology Drugs was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Sterile Injectable Drugs Market- Segmentation Analysis:

The Global Sterile Injectable Drugs Market is segmented based on Drug Type, Route of Administration, Drug Class, End-User, and Region.

The market is divided into five categories based on Drug Type: Monoclonal Antibodies (mAbs), Cytokines, Insulin, and Antibiotics. Monoclonal Antibodies (mAbs) hold the highest priority in the Sterile Injectable Drugs Market due to their broad application in treating cancers and autoimmune diseases. Insulin follows for its critical role in diabetes management, with Vaccines, Cytokines, and Antibiotics being secondary.

The market is divided into three categories based on the Route of Administration: Intravenous, Intramuscular, and Subcutaneous. Intravenous administration is the highest priority in the Sterile Injectable Drugs Market due to its rapid onset and effectiveness in acute conditions. Subcutaneous is next for its ease of use in chronic treatments, followed by Intramuscular for specific applications.

Sterile Injectable Drugs Market- Geographical Insights

North America leads the market due to its advanced healthcare infrastructure, high adoption of innovative medical technologies, and substantial investment in drug research and development. The United States, in particular, shows a high demand for sterile injectables, driven by the large patient population and robust healthcare system. Europe follows closely, supported by strong healthcare systems in countries such as Germany, France, and the UK, and an increasing focus on biologics and personalized medicine. The Asia-Pacific region is witnessing rapid growth due to the rising incidence of chronic diseases, expanding healthcare infrastructure, and increased healthcare spending in countries like China and India. Latin America and the Middle East & Africa are emerging markets, showing potential due to improving healthcare facilities and growing awareness of advanced treatments.

Sterile Injectable Drugs Market- Competitive Landscape:

Major pharmaceutical companies such as Pfizer Inc., Johnson & Johnson, and Roche are leading the market, leveraging their vast expertise in drug development and manufacturing to deliver advanced sterile injectables. These companies are investing heavily in research to develop new formulations and improve existing products, addressing the increasing demand for effective treatments for chronic conditions. Additionally, strategic mergers and acquisitions are common as companies aim to expand their product portfolios and market presence. Emerging players are also entering the market, offering novel solutions and targeting niche segments with specialized products. The competitive environment is further shaped by the need to comply with rigorous regulatory standards and ensure high-quality production, driving continuous innovation and improvements in sterile injectable technologies.

Recent Developments:

In June 2024, Sharp Services announced a significant expansion in Macungie, Pennsylvania, adding 157,500 square feet to enhance its sterile injectable capabilities. This facility will support increased demand for biologics and injectable medicines, anticipating the addition of 75-100 new employees.

In July 2023, WuXi STA launched a fully automated potency sterile injectable manufacturing line in Wuxi City, China, with an annual capacity of 12 million units. The facility features advanced isolation systems, ensuring quality and minimizing contamination during the production of various dosage forms.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL STERILE INJECTABLE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Baxter International Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V. (now part of Viatris)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL STERILE INJECTABLE DRUGS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Monoclonal Antibodies (mAbs)
  • Cytokines
  • Insulin
  • Vaccines
  • Antibiotics

GLOBAL STERILE INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)
  • Others

GLOBAL STERILE INJECTABLE DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Therapeutic Drugs
  • Anticoagulants
  • Oncology Drugs
  • Cardiovascular Drugs
  • Anti-Infective Drugs

GLOBAL STERILE INJECTABLE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Research Institutes

GLOBAL STERILE INJECTABLE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Sterile Injectable Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Sterile Injectable Drugs Market Snippet by Drug Type
    • 2.1.2. Sterile Injectable Drugs Market Snippet by Route of Administration
    • 2.1.3. Sterile Injectable Drugs Market Snippet by Drug Class
    • 2.1.4. Sterile Injectable Drugs Market Snippet by End-User
    • 2.1.5. Sterile Injectable Drugs Market Snippet by Country
    • 2.1.6. Sterile Injectable Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Sterile Injectable Drugs Key Market Trends

  • 3.1. Sterile Injectable Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Sterile Injectable Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Sterile Injectable Drugs Market Opportunities
  • 3.4. Sterile Injectable Drugs Market Future Trends

4. Sterile Injectable Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Sterile Injectable Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Sterile Injectable Drugs Market Landscape

  • 6.1. Sterile Injectable Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Sterile Injectable Drugs Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Monoclonal Antibodies (mAbs)
    • 7.1.3. Cytokines
    • 7.1.4. Insulin
    • 7.1.5. Vaccines
    • 7.1.6. Antibiotics

8. Sterile Injectable Drugs Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Intravenous (IV)
    • 8.1.3. Intramuscular (IM)
    • 8.1.4. Subcutaneous (SC)
    • 8.1.5. Others

9. Sterile Injectable Drugs Market - By Drug Class

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 9.1.2. Therapeutic Drugs
    • 9.1.3. Anticoagulants
    • 9.1.4. Oncology Drugs
    • 9.1.5. Cardiovascular Drugs
    • 9.1.6. Anti-Infective Drugs

10. Sterile Injectable Drugs Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Ambulatory Surgical Centers
    • 10.1.5. Research Institutes

11. Sterile Injectable Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Sterile Injectable Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Sterile Injectable Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Sterile Injectable Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Sterile Injectable Drugs Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Sterile Injectable Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Sterile Injectable Drugs Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca plc
    • 12.2.4. Baxter International Inc.
    • 12.2.5. Eli Lilly and Company
    • 12.2.6. F. Hoffmann-La Roche Ltd.
    • 12.2.7. Fresenius Kabi AG
    • 12.2.8. GlaxoSmithKline plc
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Merck & Co., Inc.
    • 12.2.11. Mylan N.V. (now part of Viatris)
    • 12.2.12. Novartis AG
    • 12.2.13. Pfizer Inc.
    • 12.2.14. Sanofi S.A.
    • 12.2.15. Sun Pharmaceutical Industries Ltd.
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us